Company news

Ocugen, Inc. news in 2023

Ocugen, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design

December 20, 2023

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

December 18, 2023

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

December 12, 2023

Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

November 28, 2023

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

November 9, 2023

Ocugen Provides Business Update with Third Quarter 2023 Financial Results

November 8, 2023

Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit

November 6, 2023

Ocugen to Host Conference Call on Thursday, November 9 at 8: 30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results

November 1, 2023

Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

October 9, 2023

Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa

October 3, 2023

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference

September 28, 2023

Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

September 26, 2023

Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board

September 20, 2023

Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023

September 19, 2023

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

September 12, 2023

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023

September 11, 2023

Ocugen Provides Business Update with Second Quarter 2023 Financial Results

August 20, 2023

Ocugen to Host Conference Call on Tuesday, August 22 at 8: 30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results

August 17, 2023

Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly

June 29, 2023

Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders

June 8, 2023

Ocugen, Inc. Announces Business Advisory Board

June 4, 2023

Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock

May 23, 2023

Ocugen to Present at BIO International Convention 2023

May 22, 2023

Ocugen Provides Business Update with First Quarter 2023 Financial Results

May 4, 2023

Ocugen to Host Conference Call on Friday, May 5 at 8: 30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results

April 27, 2023

Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies

April 26, 2023

Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

April 25, 2023

Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting

April 19, 2023

Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

April 13, 2023

Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023

April 10, 2023

Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress

March 30, 2023

Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

March 26, 2023

Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference

March 6, 2023

Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer

March 5, 2023

Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results

February 27, 2023

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema

February 26, 2023

Ocugen to Present at Retinal Vascular Disease Drug Development Summit

February 16, 2023

Ocugen to Host Conference Call on Tuesday, February 28 at 8: 30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results

February 14, 2023

Ocugen Appoints Quan A. Vu as Chief Business Officer

January 31, 2023

Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference

January 30, 2023

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

January 8, 2023

Calls in 2023

Decks in 2023